Correlation between middle turbinate insertion in relation to sphenopalatine foramen and failure rates of cryotherapy and radiofrequency treatment for chronic rhinitis

Fan, Timothy M.; Chandna, Megha; Gorelik, Daniel; Takashima, Masayoshi; Yim, Michael; Rowan, Nicholas R.; Garner, Jordan J; Ohlstein, Jason F; Wu, Arthur W.; Ahmed, Omar G.

doi:10.1002/alr.23058

Cited by 7 publications

(16 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,6 The location of egress of the nerve into the PPF appears to play a significant role. 7 Understanding radiographic characteristics associated with disease remains necessary to build upon existing therapies.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vidian canal diameter: A possible link to chronic rhinitis diagnosis

Chandna

Gorelik

Takashima

et al. 2022

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

“…The anatomy of the Vidian canal has previously been explored to improve surgical approach and optimize preoperative planning 3,6 . The location of egress of the nerve into the PPF appears to play a significant role 7 . Understanding radiographic characteristics associated with disease remains necessary to build upon existing therapies.…”

mentioning

confidence: 99%

Vidian canal diameter: A possible link to chronic rhinitis diagnosis

Chandna

Gorelik

Takashima

et al. 2022

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

“…One hypothesis for this lack of improvement is inadequate treatment of nerves due to natural anatomic variations that are not addressed by the current devices/technology. 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

“…One hypothesis for this lack of improvement is inadequate treatment of nerves due to natural anatomic variations that are not addressed by the current devices/technology. 10,11 The NEUROMARK ® System, a novel multipoint impedancecontrolled RF ablation device, has been designed to address these limitations. The device comprises a two-stage design, where proximal and distal flexible leaflets conform to patient anatomy, maximizing access to nerve-rich areas on the lateral wall of the nasal cavity, and allowing more posterior placement than the other available devices.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical evaluation of a novel multipoint radiofrequency ablation device to treat chronic rhinitis

Reh¹,

Lay

Davis

et al. 2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

Objective Safety and efficacy of the NEUROMARK® system for treating chronic rhinitis. Methods A prospective, single‐arm, multicenter study was performed on adults with chronic rhinitis who underwent radiofrequency ablation to the posterior nasal nerves. Primary endpoints were device‐related serious adverse events (SAEs) at 1 month and change from baseline in visual analog scale nasal symptom scale (VAS NSS) for rhinorrhea and nasal congestion at 3 months. Total nasal symptom score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated. Results Thirty‐six participants were enrolled and completed follow‐up at 1 and 3 months. Mean VAS NSS scores for rhinorrhea and nasal congestion demonstrated significant improvement at 3 months (both p < .0001). The mean percent changes from baseline in VAS rhinorrhea and nasal congestion were 53% and 55%, respectively. Total scores and all individual rTNSS items significantly improved (all p < .001) over the measured interval. Percent responder rate (≥30% reduction from baseline in total rTNSS) at 3 months was 78%. The total mean mini RQLQ scores, as well as all subdomains, improved significantly (all p < .0001). At 3 months, 89% of participants reported a minimal clinically important difference of ≥0.4 point improvement in the mini RQLQ score. No SAEs occurred during the study. Conclusions The NEUROMARK System is a novel radiofrequency ablation device that provides safe and effective treatment to the posterior nasal nerves for patients with chronic rhinitis. Study participants experienced statistically significant and clinically meaningful improvement in symptoms and quality of life assessments at 3 months post‐procedure. Trial Registration The study is registered at www.clinicaltrials.gov with the unique identifier of NCT05324397. Level of Evidence 4.

show abstract